LL-37: The Immune Peptide That Does Everything
LL-37
37 amino acids
LL-37 is the only cathelicidin antimicrobial peptide produced by the human body, active against bacteria, viruses, fungi, and biofilms.
Fabisiak et al., Pharmacological Reports, 2016
Fabisiak et al., Pharmacological Reports, 2016
View as imageOf the thousands of peptides circulating through the human body, LL-37 holds a singular distinction: it is the only member of the cathelicidin family of antimicrobial peptides that humans produce.[1] That sole-member status belies its range. Since its identification in the late 1990s, LL-37 has been linked to direct microbial killing, viral neutralization, wound repair, immune cell recruitment, inflammation regulation, and even cancer biology. It is produced by neutrophils, macrophages, epithelial cells lining the skin, lungs, and gut, and its expression rises sharply during infection and injury.
What makes LL-37 unusual among antimicrobial peptides is the breadth of its non-antimicrobial functions. It does not simply punch holes in bacterial membranes and stop there. It acts as a signaling molecule, a chemoattractant, a mediator between innate and adaptive immunity, and a regulator of tissue repair.[2] This article maps the full evidence landscape across each of those roles. For a deeper look at how LL-37 interacts with specific immune cells, see How LL-37 Activates Neutrophils and Dendritic Cells. For the paradox of its inflammatory effects, see LL-37's Dual Role: Anti-Inflammatory and Pro-Inflammatory Effects.
Key Takeaways
- LL-37 killed extracellular Staphylococcus aureus at nanomolar concentrations, outperforming conventional antibiotics doxycycline and cefazolin in a 2013 comparison study (Noore et al.)
- A randomized clinical trial found LL-37 at 0.5 mg/mL accelerated venous leg ulcer healing at a rate approximately six times faster than placebo over four weeks (Gronberg et al., 2014)
- LL-37 reduced influenza A viral titers and increased survival in infected mice, demonstrating antiviral activity independent of its antibacterial mechanism (Barlow et al., 2011)
- Vitamin D directly upregulates LL-37 gene expression in human keratinocytes through retinoid X receptor alpha signaling (Svensson et al., 2016)
- LL-37 complexed with self-DNA activates plasmacytoid dendritic cells in psoriasis, driving interferon production and disease amplification (Herster et al., 2020)
- In inflammatory bowel disease models, LL-37 protected intestinal epithelial barrier integrity and accelerated wound closure in colonocytes (Otte et al., 2009)
What Is LL-37 and Where Does It Come From?
LL-37 is a 37-amino-acid peptide cleaved from the C-terminus of a larger precursor protein called human cationic antimicrobial protein 18 (hCAP-18). The gene encoding hCAP-18 is CAMP (cathelicidin antimicrobial peptide), located on chromosome 3. Neutrophils store hCAP-18 in their specific granules and release it during degranulation, whereupon the serine protease proteinase 3 cleaves it to produce the active LL-37 fragment.[1]
The peptide carries a net positive charge of +6 and adopts an amphipathic alpha-helical structure in membrane-like environments. This structure is central to its mechanism: the positively charged face binds to negatively charged bacterial membranes, while the hydrophobic face inserts into the lipid bilayer. But LL-37 is not confined to neutrophils. It is expressed in monocytes, natural killer cells, mast cells, B cells, and T cells, as well as in epithelial cells of the skin, airways, urinary tract, gastrointestinal tract, and reproductive system.[3]
This broad tissue distribution hints at why LL-37 is involved in so many biological processes. It is positioned at virtually every interface where the body meets the outside world.
How LL-37 Kills Bacteria
The primary mechanism is membrane disruption. LL-37 binds to the lipopolysaccharide (LPS) layer of Gram-negative bacteria or the lipoteichoic acid of Gram-positive species, then inserts into the cytoplasmic membrane, forming pores or inducing membrane destabilization that leads to cell lysis. This mode of killing is fast, typically occurring within minutes, which is one reason bacteria have had difficulty developing resistance to it.
In a 2013 comparative study, Noore et al. tested LL-37 against Staphylococcus aureus alongside lactoferricin B, doxycycline, and cefazolin. LL-37 killed extracellular S. aureus at nanomolar concentrations. Lactoferricin B required micromolar concentrations to achieve comparable killing, and the conventional antibiotics performed less efficiently at equivalent doses.[4] More relevant to chronic infections, LL-37 was also effective against intracellular S. aureus residing within keratinocytes, a reservoir that conventional antibiotics struggle to reach.[4]
Beyond planktonic bacteria, LL-37 disrupts biofilms, the structured microbial communities that cause chronic wound infections, implant infections, and antibiotic-resistant conditions. The peptide prevents biofilm formation at sub-inhibitory concentrations and can partially degrade established biofilms, a property that has generated interest in its use as a wound-healing agent.
LL-37 also works against fungi (Candida albicans being the most studied) and parasites. Its broad-spectrum activity stems from a fundamental structural advantage: it targets the lipid bilayer itself rather than a specific molecular receptor. Because all microbes share the basic feature of negatively charged membranes, they cannot easily evolve resistance without fundamentally altering their membrane composition. This contrasts sharply with conventional antibiotics, which target specific enzymes or ribosomal subunits that bacteria can mutate away from. For more on antimicrobial peptide mechanisms, see How Antimicrobial Peptides Kill Bacteria: Pore Formation Explained. The broader question of whether antimicrobial peptides can address the antibiotic resistance crisis is explored in Antimicrobial Peptides as Alternatives to Antibiotics: Can They Solve Resistance?.
Antiviral Activity
LL-37's antimicrobial portfolio extends beyond bacteria. Barlow et al. (2011) demonstrated that LL-37 reduced influenza A virus replication in vitro and increased survival in mice infected with influenza. The mechanism was distinct from surfactant protein D, another innate defense molecule: LL-37 appeared to directly damage viral membranes and also enhanced the uptake of viral particles by immune cells.[5]
Subsequent work has shown antiviral effects against respiratory syncytial virus, herpes simplex virus, HIV, and vaccinia virus, though the mechanisms vary by pathogen. In some cases, LL-37 disrupts the viral envelope directly. In others, it enhances the interferon response or promotes viral uptake by phagocytes.
The COVID-19 pandemic renewed interest in LL-37's antiviral properties. Crane-Godreau et al. (2020) proposed that vitamin D deficiency suppresses LL-37 expression, potentially increasing susceptibility to SARS-CoV-2. Their analysis linked geographic regions with low vitamin D status and high air pollution to worse COVID-19 outcomes, with LL-37 suppression as a proposed mediating factor.[6] This remains a hypothesis rather than a confirmed mechanism, but the epidemiological correlations have been striking. It is worth noting that several proposed COVID-19 interventions based on immunological plausibility failed to demonstrate benefit in randomized trials. The vitamin D-LL-37-COVID connection remains at the hypothesis stage.
Wound Healing: From Lab Bench to Clinical Trial
LL-37 participates in wound healing through multiple pathways. It promotes keratinocyte migration, stimulates angiogenesis through FPRL-1 receptor signaling, induces growth factor expression, and recruits immune cells to the wound site. Adase et al. (2016) showed that LL-37 enhanced the ability of non-coding double-stranded RNA (a damage-associated molecular pattern released during tissue injury) to induce growth factor expression in keratinocytes, endothelial cells, and fibroblasts, accelerating the wound repair cascade.[7]
These preclinical findings have translated into one notable clinical trial. Gronberg et al. (2014) conducted a randomized, double-blind, placebo-controlled trial of synthetic LL-37 applied to hard-to-heal venous leg ulcers in 34 participants. The peptide was applied topically at three concentrations (0.5, 1.6, and 3.2 mg/mL) for four weeks after a three-week placebo run-in period. At 0.5 mg/mL, the healing rate constant was approximately six times higher than placebo. At 1.6 mg/mL, it was approximately three times higher. No serious adverse events were attributed to the treatment.[8]
The inverted dose-response (lower concentration outperforming higher ones) is unusual but consistent with LL-37's known cytotoxicity at high concentrations. Above certain thresholds, LL-37 can damage host cells alongside microbial ones. This trial remains the only completed randomized controlled trial of exogenous LL-37 in humans, and larger confirmatory studies have not yet been reported.
The Vitamin D Connection
One of the most clinically relevant aspects of LL-37 biology is its regulation by vitamin D. The CAMP gene contains a vitamin D response element (VDRE) in its promoter region. When 1,25-dihydroxyvitamin D3 (the active form of vitamin D) binds the vitamin D receptor, it upregulates CAMP transcription and increases LL-37 production.
Svensson et al. (2016) showed that vitamin D treatment significantly increased both CAMP gene expression and LL-37 protein levels in human keratinocytes. The effect required retinoid X receptor alpha (RXR-alpha) but was independent of vitamin D receptor coactivator status, clarifying the molecular pathway.[9]
This connection has major implications for infectious disease. Chung et al. (2020) reviewed the vitamin D-cathelicidin axis as a crossroads between protective immunity and pathological inflammation. In tuberculosis, vitamin D-induced cathelicidin production by macrophages was a key antimicrobial mechanism.[10] Al-Jaberi et al. (2022) confirmed this pathway in a clinical context, demonstrating that macrophages from a patient population with vitamin D deficiency showed reduced cathelicidin production and impaired Mycobacterium tuberculosis killing.[11]
The vitamin D-LL-37 pathway partially explains why vitamin D supplementation has shown variable effects in clinical trials of respiratory infection prevention. LL-37 induction may be one mechanism among several, and outcomes likely depend on baseline vitamin D status, infection type, and genetic variation in the VDR and CAMP genes. For a detailed look at this relationship, see Vitamin D and LL-37: Why Sunlight Boosts Your Antimicrobial Peptides.
Immunomodulation: Beyond Killing
LL-37 does not simply kill pathogens and step aside. It actively shapes the immune response in ways that can be either protective or harmful depending on context.
Scott et al. (2002) published a foundational study demonstrating that LL-37 is a potent antisepsis agent. It inhibited macrophage activation by LPS, lipoteichoic acid, and noncapped lipoarabinomannan, reducing the production of pro-inflammatory cytokines TNF-alpha and nitric oxide. At the same time, LL-37 selectively upregulated certain chemokines, recruited neutrophils and monocytes to infection sites, and enhanced phagocytic clearance.[2]
Pinheiro da Silva and Machado (2017) reviewed this dual nature in systemic inflammation. Cathelicidins dampen excessive inflammatory responses (protective in sepsis) while simultaneously amplifying immune cell recruitment and activation (protective against focal infection). The balance between these effects determines whether LL-37 acts as a healing signal or a driver of tissue damage.[12]
This duality is not a flaw in the peptide's design. It reflects the immune system's need for context-dependent responses. The same molecule that prevents septic shock by neutralizing circulating endotoxin also amplifies local immune activity at the site of a skin infection. The challenge for therapeutic development is harnessing one effect without triggering the other. For a deep dive into this paradox, see LL-37's Dual Role: Anti-Inflammatory and Pro-Inflammatory Effects.
LL-37 in Autoimmune Disease
The same properties that make LL-37 an effective immune activator can become liabilities when the peptide turns against the host.
Psoriasis
The most established autoimmune connection involves psoriasis. LL-37 binds to self-DNA and self-RNA released from dying cells, forming complexes that activate plasmacytoid dendritic cells through Toll-like receptors 7 and 9. This triggers type I interferon production, amplifying the inflammatory cascade characteristic of psoriatic plaques.
Herster et al. (2020) overturned a previous assumption about this pathway. DNA had been considered the key component of neutrophil extracellular traps (NETs) driving psoriatic inflammation. Their work showed that RNA, not DNA, was the critical nucleic acid. NET-associated RNA complexed with LL-37 activated keratinocytes to produce IL-6 and TNF, creating a self-amplifying inflammatory loop.[13]
Rosacea
LL-37 is also central to rosacea pathogenesis. In rosacea-affected skin, the serine protease kallikrein 5 is overactive, producing abnormally high levels of LL-37 fragments with altered biological activity. Yoon et al. (2021) demonstrated that LL-37 drives rosacea-like skin inflammation through NLRP3 inflammasome activation. Mice deficient in NLRP3 were protected from LL-37-induced skin inflammation, identifying a specific molecular target for potential intervention.[14]
Lupus and Other Conditions
Pahar et al. (2020) reviewed LL-37's involvement in systemic lupus erythematosus, where LL-37-DNA complexes similarly activate plasmacytoid dendritic cells and drive interferon-alpha production. The same review cataloged LL-37's associations with rheumatoid arthritis, atherosclerosis, and type 1 diabetes, though the evidence for causal involvement in these conditions is less developed than in psoriasis.[15]
The autoimmune research presents a complicated picture for therapeutic development. Systemically boosting LL-37 could theoretically worsen autoimmune conditions, while topical or localized delivery might avoid this risk.
LL-37 in Gastrointestinal Health
The gastrointestinal tract is one of LL-37's primary theaters of action. The peptide is expressed by epithelial cells throughout the stomach, small intestine, and colon, and its expression increases during infection and inflammation.
Otte et al. (2009) showed that LL-37 protected intestinal epithelial barrier integrity in HT-29 and Caco-2 cell models. It enhanced wound closure in colonocyte monolayers, suggesting a role in mucosal repair following injury.[16]
Sun et al. (2016) reviewed LL-37's roles in inflammatory bowel disease specifically. In ulcerative colitis and Crohn's disease, cathelicidin expression patterns are altered. LL-37 modulates immune responses in the gut by suppressing pro-inflammatory cytokine production while enhancing epithelial repair, positioning it as both a biomarker and a potential therapeutic target for IBD.[17]
Wu et al. (2010) broadened this perspective, reviewing cathelicidin's therapeutic potential across GI disorders including peptic ulcer disease, IBD, and colorectal cancer. Cathelicidin expression in the stomach increased during Helicobacter pylori infection, and exogenous cathelicidin administration reduced gastric inflammation in animal models.[3]
LL-37 and Cancer: A Double-Edged Sword
Chen et al. (2018) comprehensively reviewed LL-37's roles in cancer biology. The peptide has been reported to both promote and suppress tumor growth depending on the cancer type.[18]
Tumor-promoting effects have been observed in ovarian cancer (where LL-37 activated EGFR and stimulated cell proliferation), lung cancer (enhanced migration and invasion via FPRL1 signaling), and breast cancer (promoted tumor cell survival through P2X7 receptor activation). In melanoma, LL-37 promoted YB-1 expression and increased cell viability and invasion in vitro.
Tumor-suppressing effects have been demonstrated in gastric cancer (LL-37 induced apoptosis through mitochondrial depolarization) and colon cancer (cell cycle arrest at G0/G1 phase). In some experimental systems, LL-37 enhanced the cytotoxic activity of natural killer cells against tumor targets, suggesting an immune-mediated anti-tumor pathway.
This divergence likely reflects differences in receptor expression across tumor types and the local microenvironment in which LL-37 operates. The same peptide activating different receptor cascades in different tissues produces opposite outcomes. The cancer evidence remains entirely preclinical, and no human trials of LL-37 for cancer have been reported. The contradictory results across tumor types also suggest that therapeutic targeting of LL-37 in oncology would require tumor-specific approaches rather than systemic modulation.
What the Evidence Supports and Where It Falls Short
The strongest evidence for LL-37 centers on three areas:
Direct antimicrobial activity is well established across hundreds of studies. LL-37 kills a broad spectrum of bacteria, fungi, and viruses through membrane disruption and related mechanisms. This evidence is mechanistically clear and reproducible.
Vitamin D regulation of LL-37 expression is molecularly defined. The pathway from vitamin D receptor activation through CAMP gene transcription to LL-37 protein production has been demonstrated in multiple cell types and confirmed in human populations.
Wound healing has the strongest clinical translation, with one randomized controlled trial showing accelerated healing of venous leg ulcers. However, this was a small trial (34 participants), and the inverted dose-response curve needs explanation in larger studies.
The weakest evidence exists for systemic therapeutic applications. While LL-37's immunomodulatory properties are well documented in vitro and in animal models, the dual nature of these effects (anti-inflammatory in some contexts, pro-inflammatory in others) creates substantial challenges for systemic drug development. The autoimmune associations with psoriasis and lupus add a cautionary dimension.
One persistent gap in the literature is the absence of pharmacokinetic data for exogenous LL-37 in humans. The Gronberg wound healing trial used topical application, bypassing systemic exposure. How LL-37 behaves when administered subcutaneously or intravenously, its half-life, distribution, and metabolism in humans, remains incompletely characterized in published research.
A second gap involves the relationship between circulating LL-37 levels and disease outcomes. While elevated LL-37 has been measured in psoriatic skin, rosacea lesions, and inflamed joints, and reduced LL-37 has been found in some infection-prone populations, no large prospective study has established LL-37 as a validated clinical biomarker with defined reference ranges. The measurement methods also vary across studies (ELISA, mass spectrometry, immunohistochemistry), making cross-study comparisons difficult.
Finally, LL-37 is susceptible to proteolytic degradation in serum, which limits its potential as a systemic therapeutic in its native form. Research into modified LL-37 derivatives, nanoparticle encapsulation, and gene therapy approaches (delivering the CAMP gene rather than the peptide itself) represents the frontier of translational work. For context on how antimicrobial peptides interact with the broader microbiome, see How Your Antimicrobial Peptides Shape Your Microbiome.
The Bottom Line
LL-37 is the only human cathelicidin, a 37-amino-acid peptide with confirmed activity against bacteria, viruses, fungi, and biofilms, plus roles in wound healing, immune modulation, and inflammation. One small clinical trial supports its efficacy in accelerating wound healing. Its regulation by vitamin D is molecularly established. However, LL-37's dual inflammatory nature and associations with autoimmune conditions like psoriasis and lupus complicate therapeutic development, and large-scale human trials remain absent for most proposed applications.